Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
20.08
-0.69 (-3.32%)
At close: Jun 20, 2025, 4:00 PM
20.05
-0.03 (-0.15%)
After-hours: Jun 20, 2025, 7:59 PM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $744.86M in the quarter ending March 31, 2025, with 80.15% growth. This brings the company's revenue in the last twelve months to $2.23B, up 59.15% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+59.15%
P/S Ratio
0.86
Revenue / Employee
$1,627,821
Employees
1,372
Market Cap
1.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SRPT News
- 2 days ago - Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand - Benzinga
- 2 days ago - SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT) - GlobeNewsWire
- 4 days ago - SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT) - GlobeNewsWire
- 5 days ago - SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire
- 5 days ago - SRPT Stock: What's Happening With Sarepta Therapeutics? - Forbes
- 6 days ago - Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy - Seeking Alpha
- 6 days ago - Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity - Seeking Alpha
- 6 days ago - Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga